Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.Encouraging VAXI...

Related Keywords

Australia ,Sydney ,New South Wales ,San Diego ,California ,United States ,American ,Youtube Imugenelimited ,Leslie Chong ,Daneng Li ,Heather Armstrong ,Matt Wright ,Imugene Limited ,Twitter ,American Association For Cancer Research ,Linkedin Imugene ,Department Of Medical Oncology Therapeutics Research ,American Association ,Cancer Research ,Annual Meeting ,Medical Oncology ,Therapeutics Research ,Presentation Number ,Tuesday April ,First In Human Phasei Clinical Trials ,Dose Escalation Safety ,Tolerability Study ,Administered Intratumorally ,Adult Patients ,Advanced Solid ,Chief Executive ,